enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Casirivimab/imdevimab - Wikipedia

    en.wikipedia.org/wiki/Casirivimab/imdevimab

    In the European Union, the combination is indicated for the treatment of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) who do not require supplemental oxygen and who are at high increased risk of progressing to severe COVID‑19; [10] and for the prevention of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms ...

  3. Regeneron's Coronavirus Antibody Cocktail Study Data ... - AOL

    www.aol.com/news/regenerons-coronavirus-antibody...

    Regeneron (REGN) announces encouraging initial data from its seamless phase I/II/III study, evaluating antibody cocktail candidate, REGN-COV2, in non-hospitalized patients with COVID-19.

  4. Tixagevimab/cilgavimab - Wikipedia

    en.wikipedia.org/wiki/Tixagevimab/cilgavimab

    In contrast to pre-exposure prophylaxis, the Storm Chaser study of already-exposed people (post-exposure prophylaxis) did not meet its primary endpoint, which was prevention of symptomatic COVID-19 in people already exposed. AZD7442 was administered to 1,000 volunteers who had recently been exposed to COVID.

  5. Bebtelovimab - Wikipedia

    en.wikipedia.org/wiki/Bebtelovimab

    Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.

  6. Israel study: 4th vaccine shows limited results with Omicron

    www.aol.com/news/israel-study-4th-vaccine-shows...

    An Israeli hospital on Monday said preliminary research indicates a fourth dose of the coronavirus vaccine provides only limited defense against the omicron variant that is raging around the world.

  7. Study confirms GSK-Vir antibody drug reduces ... - AOL

    www.aol.com/finance/study-confirms-gsk-vir...

    In a study of 1,057 patients, sotrovimab resulted in a 79% reduction in risk of hospitalization for more than 24 hours or death due to any cause, the companies said on Monday.

  8. Convidecia - Wikipedia

    en.wikipedia.org/wiki/Convidecia

    In April, Ad5-nCoV became the first COVID-19 vaccine candidate in the world to begin Phase II trials. [30] The Phase II trial results were published in the peer-reviewed journal The Lancet in August 2020, and noted neutralizing antibody and T cell responses based on statistical analyses of data involving 508 eligible participants. [31]

  9. COVID-19 datasets - Wikipedia

    en.wikipedia.org/wiki/COVID-19_datasets

    The University of Montreal and Mila created the "COVID-19 Image Data Collection" in March which is a public data repository of chest imaging. [ 25 ] [ 26 ] [ 27 ] The Medical Imaging Databank in Valencian Region released a large dataset of chest imaging from Spain.